Stockscreener 앱 받기
3.51
7.14%
-0.27
시간 외 거래:
3.51
전일 마감가:
$3.78
열려 있는:
$3.53
하루 거래량:
721.33K
Relative Volume:
0.89
시가총액:
$310.99M
수익:
$380.79M
순이익/손실:
$49.27M
주가수익비율:
5.0143
EPS:
0.7
순현금흐름:
$10.68M
1주 성능:
-9.30%
1개월 성능:
+17.00%
6개월 성능:
+19.39%
1년 성능:
+33.46%
1일 변동 폭
$3.42
$3.73
1주일 범위
$3.23
$3.85
52주 변동 폭
$1.575
$7.27
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
명칭
Amylyx Pharmaceuticals Inc
전화
617-683-0917
주소
43 THORNDIKE STREET, CAMBRIDGE
AMLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
3.51 | 310.99M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-18 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-03-18 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-11 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-07-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-01-05 | 개시 | BofA Securities | Buy |
| 2022-05-25 | 개시 | Citigroup | Buy |
| 2022-04-01 | 다운그레이드 | Goldman | Buy → Neutral |
모두보기
Amylyx Pharmaceuticals Inc 주식(AMLX)의 최신 뉴스
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Optimistic Investors Push Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Up 26% But Growth Is Lacking - simplywall.st
Amylyx Pharmaceuticals Executives Unload Massive Stock Shares! - TipRanks
Amylyx Pharmaceuticals chief medical officer sells $43,082 in stock - Investing.com
Amylyx Pharmaceuticals Executives Sell Shares to Cover Tax Obligations - TradingView
Amylyx Pharmaceuticals’ co-CEO Joshua Cohen sells $74,482 in stock - Investing.com India
Amylyx Pharmaceuticals chief legal officer sells $31,954 in stock - Investing.com
Amylyx Pharmaceuticals chief legal officer sells $31,954 in stock By Investing.com - Investing.com UK
Amylyx Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference - BioSpace
Amylyx Pharmaceuticals Set to Reveal Latest Corporate Strategy at Major Healthcare Conference - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation - markets.businessinsider.com
Does Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Still Look Hot This Week? - stocksregister.com
Charles Schwab Investment Management Inc. Lowers Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - markets.businessinsider.com
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More InformationAMLX - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Reach Out - Markets Insider
Is Amylyx Pharmaceuticals (AMLX) The Hot Biotech Stock Under $5? - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - Markets Insider
Amylyx Pharmaceuticals director Bernhardt Zeiher buys $37,005 in stock By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals director Bernhardt Zeiher buys $37,005 in stock - Investing.com India
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Analysts Think Could Fell -201.37% From Current Levels - Stocks Register
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Shareholders that lost money on Amylyx Pharmaceuticals, Inc. (AMLX) should contact Levi & Korsinsky about pending Class ActionAMLX - ACCESS Newswire
Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect - Markets Insider
AMYLYX PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals - Business Wire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga India
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation - ACCESS Newswire
What is HC Wainwright’s Estimate for AMLX FY2025 Earnings? - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out - Markets Insider
Research Analysts Issue Forecasts for AMLX Q1 Earnings - The AM Reporter
What is HC Wainwright’s Estimate for AMLX Q1 Earnings? - Defense World
Cautious Hold Rating for Amylyx Pharmaceuticals Amid Key Clinical Updates and Stable Financial Position - TipRanks
HC Wainwright Reiterates “Buy” Rating for Amylyx Pharmaceuticals (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals co-CEO Joshua Cohen sells $14,549 in stock By Investing.com - Investing.com Australia
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out - Markets Insider
Y Intercept Hong Kong Ltd Takes Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
March 2025's Top Penny Stocks To Watch - Yahoo Finance
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Up 30.5% in February - Defense World
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Amylyx Pharmaceuticals Inc (AMLX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Amylyx Pharmaceuticals chief legal officer sells $5,022 in stock By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect - ACCESS Newswire
Amylyx Pharmaceuticals co-CEO Joshua Cohen sells $14,549 in stock - Investing.com
Amylyx Pharmaceuticals chief legal officer sells $5,022 in stock - Investing.com
Buy Rating for Amylyx Pharmaceuticals: Avexitide’s Potential in Post-Bariatric Surgery Market - TipRanks
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2024 Earnings Call Transcript - Insider Monkey
Amylyx Pharmaceuticals Faces Challenges in Acquisition Strategy Amid RELYVRIO Discontinuation - TipRanks
Amylyx Pharmaceuticals Inc (AMLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):